GERN vs. LXRX
GERN (Geron Corporation) and LXRX (Lexicon Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, GERN returned -7.19%/yr vs -17.59%/yr for LXRX. Their 0.35 correlation means their historical movements had little consistent relationship.
Performance
GERN vs. LXRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GERN achieves a -2.27% return, which is significantly lower than LXRX's 100.87% return. Over the past 10 years, GERN has outperformed LXRX with an annualized return of -7.19%, while LXRX has yielded a comparatively lower -17.59% annualized return.
GERN
- 1D
- -3.73%
- 1M
- -5.15%
- 6M
- -5.84%
- YTD
- -2.27%
- 1Y
- 10.26%
- 3Y*
- -26.20%
- 5Y*
- 1.12%
- 10Y*
- -7.19%
- ALL TIME*
- -5.90%
LXRX
- 1D
- -1.28%
- 1M
- -0.43%
- 6M
- 99.14%
- YTD
- 100.87%
- 1Y
- 115.89%
- 3Y*
- 5.99%
- 5Y*
- -8.18%
- 10Y*
- -17.59%
- ALL TIME*
- -14.75%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $11.36M | $12.76M | $17.04M | |
| $6.18M | $6.21M | $7.76M |
GERN vs. LXRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
GERN Geron Corporation | -2.27% | -62.71% | 67.77% | -12.81% | 98.36% | -23.27% | 16.91% | 36.00% | -44.44% | -13.04% |
LXRX Lexicon Pharmaceuticals, Inc. | 100.87% | 55.72% | -51.73% | -19.90% | -51.52% | 15.20% | -17.59% | -37.50% | -32.79% | -28.56% |
Correlation
The correlation between GERN and LXRX is 0.27, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.27 |
Correlation (3Y) Balances recent behavior with more history. | 0.31 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.38 |
Correlation (10Y) Provides a long-term view across more market conditions. | 0.36 |
Correlation (All Time) Calculated using the full available price history since Apr 7, 2000 | 0.35 |
The correlation between GERN and LXRX shifts across timeframes, from 0.27 (1 year) to 0.38 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
GERN:
$827.56M
LXRX:
$1.03B
GERN:
-$0.10
LXRX:
-$0.07
GERN:
4.39
LXRX:
12.46
GERN:
3.77
LXRX:
4.56
GERN:
$196.12M
LXRX:
$69.64M
GERN:
$119.67M
LXRX:
$69.00M
GERN:
-$40.62M
LXRX:
-$20.38M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GERN vs. LXRX — Risk / Return Rank
GERN
LXRX
GERN vs. LXRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Geron Corporation (GERN) and Lexicon Pharmaceuticals, Inc. (LXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GERN | LXRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.30 | ||
| Sortino ratioReturn per unit of downside risk | -1.50 | ||
| Omega ratioGain probability vs. loss probability | 1.09 | 1.27 | -0.19 |
| Calmar ratioReturn relative to maximum drawdown | 0.28 | 3.42 | -3.14 |
| Martin ratioReturn relative to average drawdown | 0.61 | 7.67 | -7.06 |
Loading charts...
Drawdowns
GERN vs. LXRX - Drawdown Comparison
The maximum GERN drawdown since its inception was -98.73%, roughly equal to the maximum LXRX drawdown of -99.91%. Use the drawdown chart below to compare losses from any high point for GERN and LXRX.
Loading charts...
Drawdown Indicators
| GERN | LXRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.73% | -99.91% | +1.18% |
Max Drawdown (1Y)Largest decline over 1 year | -43.59% | -34.09% | -9.50% |
Max Drawdown (3Y)Largest decline over 3 years | -78.98% | -91.83% | +12.85% |
Max Drawdown (5Y)Largest decline over 5 years | -78.98% | -95.25% | +16.27% |
Max Drawdown (10Y)Largest decline over 10 years | -86.09% | -98.48% | +12.39% |
Current DrawdownCurrent decline from peak | -98.15% | -99.30% | +1.15% |
Average DrawdownAverage peak-to-trough decline | -86.21% | -93.30% | +7.09% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.06% | 15.17% | +4.89% |
Volatility
GERN vs. LXRX - Volatility Comparison
Geron Corporation (GERN) has a higher volatility of 16.52% compared to Lexicon Pharmaceuticals, Inc. (LXRX) at 13.63%. This indicates that GERN's price experiences larger fluctuations and is considered to be riskier than LXRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GERN | LXRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 16.52% | 13.63% | +2.89% |
Volatility (6M)Calculated over the trailing 6-month period | 46.49% | 53.49% | -7.00% |
Volatility (1Y)Calculated over the trailing 1-year period | 61.70% | 78.14% | -16.44% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 81.29% | 97.90% | -16.61% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 78.11% | 97.38% | -19.27% |
Dividends
GERN vs. LXRX - Dividend Comparison
Neither GERN nor LXRX has paid dividends to shareholders.
Financials
GERN vs. LXRX - Financials Comparison
This section allows you to compare key financial metrics between Geron Corporation and Lexicon Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
GERN vs. LXRX - Profitability Comparison
GERN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Geron Corporation reported a gross profit of 0.00 and revenue of 51.84M. Therefore, the gross margin over that period was 0.0%.
LXRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Lexicon Pharmaceuticals, Inc. reported a gross profit of 20.99M and revenue of 21.10M. Therefore, the gross margin over that period was 99.5%.
GERN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Geron Corporation reported an operating income of 158.00K and revenue of 51.84M, resulting in an operating margin of 0.3%.
LXRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Lexicon Pharmaceuticals, Inc. reported an operating income of -996.00K and revenue of 21.10M, resulting in an operating margin of -4.7%.
GERN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Geron Corporation reported a net income of -3.64M and revenue of 51.84M, resulting in a net margin of -7.0%.
LXRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Lexicon Pharmaceuticals, Inc. reported a net income of -1.04M and revenue of 21.10M, resulting in a net margin of -4.9%.
Frequently Asked Questions
GERN and LXRX have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GERN has higher volatility (16.52%) compared to LXRX (13.63%). In terms of maximum drawdown, GERN dropped -98.73% vs LXRX's -99.91%.
LXRX currently has the higher Sharpe Ratio (1.49 vs 0.20), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GERN and LXRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer